SCIENCE 37 HOLDINGS INC (SNCE) Fundamental Analysis & Valuation
NASDAQ:SNCE • US8086442071
Current stock price
5.75 USD
+0.02 (+0.35%)
At close:
5.7203 USD
-0.03 (-0.52%)
After Hours:
This SNCE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SNCE Profitability Analysis
1.1 Basic Checks
- In the past year SNCE has reported negative net income.
- SNCE had a negative operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of SNCE (-164.66%) is worse than 98.31% of its industry peers.
- SNCE's Return On Equity of -241.10% is on the low side compared to the rest of the industry. SNCE is outperformed by 88.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| ROIC | N/A |
ROA(3y)-44.02%
ROA(5y)N/A
ROE(3y)-71.84%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 29.75%, SNCE is not doing good in the industry: 72.88% of the companies in the same industry are doing better.
- The Profit Margin and Operating Margin are not available for SNCE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. SNCE Health Analysis
2.1 Basic Checks
- SNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- SNCE has more shares outstanding than it did 1 year ago.
- SNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -5.81, we must say that SNCE is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -5.81, SNCE is not doing good in the industry: 93.22% of the companies in the same industry are doing better.
- There is no outstanding debt for SNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.81 |
ROIC/WACCN/A
WACC11.9%
2.3 Liquidity
- A Current Ratio of 4.17 indicates that SNCE has no problem at all paying its short term obligations.
- The Current ratio of SNCE (4.17) is better than 62.71% of its industry peers.
- SNCE has a Quick Ratio of 4.17. This indicates that SNCE is financially healthy and has no problem in meeting its short term obligations.
- SNCE has a Quick ratio of 4.17. This is in the better half of the industry: SNCE outperforms 67.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 |
3. SNCE Growth Analysis
3.1 Past
- The earnings per share for SNCE have decreased strongly by -881.08% in the last year.
- SNCE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.21%.
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-429.41%
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-8.37%
3.2 Future
- Based on estimates for the next years, SNCE will show a decrease in Earnings Per Share. The EPS will decrease by -0.15% on average per year.
- The Revenue is expected to grow by 14.73% on average over the next years. This is quite good.
EPS Next Y-72.66%
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
EPS Next 5YN/A
Revenue Next Year-14.69%
Revenue Next 2Y-4.18%
Revenue Next 3Y3.19%
Revenue Next 5Y14.73%
3.3 Evolution
4. SNCE Valuation Analysis
4.1 Price/Earnings Ratio
- SNCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNCE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
5. SNCE Dividend Analysis
5.1 Amount
- SNCE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SNCE Fundamentals: All Metrics, Ratios and Statistics
5.75
+0.02 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04 2024-03-04/amc
Earnings (Next)05-13 2024-05-13/bmo
Inst Owners0.02%
Inst Owner Change0%
Ins Owners287.18%
Ins Owner Change0%
Market Cap34.67M
Revenue(TTM)60.27M
Net Income(TTM)-124.65M
Analysts76
Price Target14.11 (145.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.04%
Min EPS beat(2)36.97%
Max EPS beat(2)45.1%
EPS beat(4)4
Avg EPS beat(4)31.49%
Min EPS beat(4)21.57%
Max EPS beat(4)45.1%
EPS beat(8)7
Avg EPS beat(8)20.64%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)9.12%
Min Revenue beat(2)-1.56%
Max Revenue beat(2)19.79%
Revenue beat(4)3
Avg Revenue beat(4)8.87%
Min Revenue beat(4)-1.56%
Max Revenue beat(4)19.79%
Revenue beat(8)5
Avg Revenue beat(8)8.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1950%
EPS NY rev (1m)0%
EPS NY rev (3m)-1907.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.67 | ||
| P/tB | 0.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.26
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)-12.22
FCFYN/A
OCF(TTM)-7.99
OCFYN/A
SpS10
BVpS8.57
TBVpS8.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.75% | ||
| FCFM | N/A |
ROA(3y)-44.02%
ROA(5y)N/A
ROE(3y)-71.84%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 432.94% | ||
| Cap/Sales | 42.31% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z | -5.81 |
F-Score5
WACC11.9%
ROIC/WACCN/A
Cap/Depr(3y)193.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)35.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-429.41%
EPS Next Y-72.66%
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-8.37%
Revenue Next Year-14.69%
Revenue Next 2Y-4.18%
Revenue Next 3Y3.19%
Revenue Next 5Y14.73%
EBIT growth 1Y48.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.54%
EBIT Next 3Y25.26%
EBIT Next 5Y19.21%
FCF growth 1Y-173.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.62%
OCF growth 3YN/A
OCF growth 5YN/A
SCIENCE 37 HOLDINGS INC / SNCE Fundamental Analysis FAQ
What is the fundamental rating for SNCE stock?
ChartMill assigns a fundamental rating of 2 / 10 to SNCE.
Can you provide the valuation status for SCIENCE 37 HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to SCIENCE 37 HOLDINGS INC (SNCE). This can be considered as Overvalued.
Can you provide the profitability details for SCIENCE 37 HOLDINGS INC?
SCIENCE 37 HOLDINGS INC (SNCE) has a profitability rating of 0 / 10.
What is the earnings growth outlook for SCIENCE 37 HOLDINGS INC?
The Earnings per Share (EPS) of SCIENCE 37 HOLDINGS INC (SNCE) is expected to decline by -72.66% in the next year.